Irvine-based Spectrum Pharmaceuticals recently completed its acquisition of RIT Oncology LLC to commercialize Zevalin, a therapy for Non-Hodgkin's Lymphoma, in the United States.
Through the agreement, Spectrum holds full ownership of RIT and will be responsible for all future activities relating to Zevalin. The company will also book all of Zevalin's revenues.
“We are excited to have 100 percent ownership of Zevalin,” says the company's president, chairman and CEO, Rajesh C. Shrotriya, M.D. “Recent clinical data have dramatically underscored the clinical benefits of ZEVALIN in NHL (Non-Hodgkin's Lymphoma)."
San Clemente's STEMTech to Obama: What about adult stem cells?
Test results in: Clarient of Aliso Viejo's revenues soar
"OC METRO Minute," March 13: UCI's geriatrics program receives funding from Donald W. Reynolds Foundation
"OC METRO Minute," March 11: Epinex's diabetes monitoring device